FindTrial
Sign In

Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosis

Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosis: a randomized clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201605169014N99
Enrollment
120
Registered
2016-05-20
Start date
2006-06-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis. Idiopathic osteoporosis

Interventions

Intervention 1: Intervention group 1: Teriparatide 20 mcg daily subcutaneously for one year. Intervention 2: Intervention group 2: Alendronate 70 mg weekly orally for one year. Intervention 3: Interve
Treatment - Drugs
Intervention group 1: Teriparatide 20 mcg daily subcutaneously for one year.
Intervention group 2: Alendronate 70 mg weekly orally for one year.
Intervention group 3: Zoledronic Acid 4 mg subcutaneously at the beginning of treatment and 6 months later.
Intervention group 4: Teriparatide 20 mcg daily subcutaneously for 6 months and then Alendronate 70 mg weekly orally for 6 months.

Sponsors

Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
44 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: primary osteoporosis; T-score less than -2.5 in the lumbar spine or femoral neck; female; age of 44 to 99 years. Exclusion criteria: secondary osteoporosis; using prednisolone more than 3 months; rheumatologic disease; malignancy; hypothyroidism; renal failure; history of surgery of parathyroid gland.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using Dual X-ray Absorptiometry.—

Secondary

MeasureTime frame
Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using T-score.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Fatahi

Farshchian Hospital

rezafatahi1616@gmail.com+98 81 3838 0283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026